IN2014CN02448A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02448A
IN2014CN02448A IN2448CHN2014A IN2014CN02448A IN 2014CN02448 A IN2014CN02448 A IN 2014CN02448A IN 2448CHN2014 A IN2448CHN2014 A IN 2448CHN2014A IN 2014CN02448 A IN2014CN02448 A IN 2014CN02448A
Authority
IN
India
Prior art keywords
glucagon peptides
obesity
treatment
present
peptides
Prior art date
Application number
Inventor
Jesper F Lau
Thomas Kruse
Henning Thøgersen
Ulrich Sensfuss
Peter Kresten Nielsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IN2014CN02448A publication Critical patent/IN2014CN02448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)

Abstract

The present invention relates to novel glucagon peptides to the use of said glucagon peptides in therapy to methods of treatment comprising administration of said glucagon peptides to patients in need thereof and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia diabetes and obesity as well as a variety of diseases or conditions associated with hyperglycemia diabetes and obesity.
IN2448CHN2014 2011-09-23 2012-09-21 IN2014CN02448A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11182476 2011-09-23
US201161539148P 2011-09-26 2011-09-26
PCT/EP2012/068649 WO2013041678A1 (en) 2011-09-23 2012-09-21 Novel glucagon analogues

Publications (1)

Publication Number Publication Date
IN2014CN02448A true IN2014CN02448A (en) 2015-06-19

Family

ID=47911932

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2448CHN2014 IN2014CN02448A (en) 2011-09-23 2012-09-21

Country Status (17)

Country Link
US (4) US8541368B2 (en)
EP (1) EP2758426B1 (en)
JP (2) JP6352806B2 (en)
KR (1) KR20140070612A (en)
CN (1) CN104093735B (en)
AR (1) AR088161A1 (en)
AU (1) AU2012311484B2 (en)
BR (1) BR112014006684A2 (en)
CA (1) CA2849673A1 (en)
IL (1) IL231199A0 (en)
IN (1) IN2014CN02448A (en)
MX (1) MX354705B (en)
MY (1) MY167234A (en)
RU (2) RU2610175C2 (en)
TW (1) TWI596110B (en)
WO (1) WO2013041678A1 (en)
ZA (1) ZA201401603B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070029247A (en) * 2004-07-08 2007-03-13 노보 노르디스크 에이/에스 Polypeptide protracting tags
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
EP2758426B1 (en) * 2011-09-23 2019-08-07 Novo Nordisk A/S Novel glucagon analogues
CN104470948B (en) 2012-05-03 2018-06-15 西兰制药公司 GIP-GLP-1 double agonists compound and method
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
JP2016503771A (en) 2012-12-21 2016-02-08 サノフイ Exendin-4 derivative
PT2986313T (en) * 2013-04-18 2019-09-10 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
AU2014255608B2 (en) * 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
BR112015030948A2 (en) 2013-06-20 2017-09-19 Novo Nordisk As GLP-1 DERIVATIVES AND THEIR USES
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AR098065A1 (en) 2013-10-17 2016-04-27 Zealand Pharma As GLUCAGON ANALOGS ACCILATED
EA035688B1 (en) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Glucagon-glp-1-gip triple agonist compounds
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
RU2016134425A (en) 2014-02-18 2018-03-20 Ново Нордиск А/С STABLE GLUCAGON ANALOGUES AND THEIR APPLICATION FOR THE TREATMENT OF HYPOGLYCEMIA
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (en) * 2014-09-23 2016-11-09 蒋先兴 Oxyntomodulin analogs
EP3204408B1 (en) 2014-10-10 2020-05-06 Novo Nordisk A/S Stable glp-1 based glp-1/glucagon receptor co-agonists
EP3985016A1 (en) 2014-10-29 2022-04-20 Zealand Pharma A/S Gip agonist compounds and methods
ES2739289T3 (en) 2014-11-27 2020-01-30 Novo Nordisk As GLP-1 derivatives and their uses
JP6691125B2 (en) 2014-12-17 2020-04-28 ノヴォ ノルディスク アー／エス GLP-1 derivative and use thereof
JOP20200119A1 (en) 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
KR20170137198A (en) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 Acylated glucagon analogs
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
US10308701B2 (en) * 2015-07-22 2019-06-04 Purdue Research Foundation Modified glucagon molecules
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
CA3010756A1 (en) * 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents
SG11202000135PA (en) * 2017-07-13 2020-02-27 Fuji Oil Holdings Inc Peptide
JP7339236B2 (en) 2017-07-19 2023-09-05 ノヴォ ノルディスク アー／エス Bifunctional compound
EP3689942B1 (en) 2017-09-29 2024-06-19 Hanmi Pharm. Co., Ltd. Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
EP3921336B1 (en) * 2019-02-05 2023-03-01 Eli Lilly And Company Glucagon analog agonists and methods of using the same
EP4076492A4 (en) * 2019-12-20 2024-01-17 Merck Sharp & Dohme Llc Pcsk9 antagonist compounds
TW202227474A (en) * 2020-12-18 2022-07-16 丹麥商諾佛 儂迪克股份有限公司 Co-agonists of the glp-1 and amylin receptors
CN116710462A (en) 2021-01-20 2023-09-05 维京治疗公司 Compositions and methods for treating metabolic disorders and liver diseases
CN113759048B (en) * 2021-10-14 2022-06-21 成都普康唯新生物科技有限公司 Inspection method of mono-tert-butyl octadecanedioate

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
ZA90533B (en) 1989-02-01 1990-10-31 Shionogi & Co A method for the production of glucagon
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
HUP9901132A2 (en) 1995-09-08 1999-07-28 Novo Nordisk A/S 2-alkylpyrrolidines
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
WO1997041120A1 (en) 1996-07-26 1997-11-06 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
PT944648E (en) 1996-08-30 2007-06-26 Novo Nordisk As Glp-1 derivatives
EP0958296B1 (en) 1996-12-31 2003-07-30 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1997041119A1 (en) 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
JP2003514508A (en) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ Glucagon antagonist / adverse agent
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR9810592A (en) 1997-07-16 2000-09-12 Novo Nordisk As Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
ATE212991T1 (en) 1997-12-02 2002-02-15 Reddy Research Foundation THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE DERIVATIVES WITH ANTIDIABETIC, HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE PROPERTIES
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
AU6325699A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
WO2000023415A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527520A (en) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ New compounds, their production and use
WO2000023425A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527503A (en) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ New compounds, their preparation and use
DK1140945T3 (en) 1998-12-18 2003-09-15 Novo Nordisk As Condensed 1,2,4-thiadiazine derivatives, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
EP1147092A1 (en) 1999-01-18 2001-10-24 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
TR200103851T2 (en) 1999-04-16 2002-04-22 Dr. Reddy' S Research Foundation New polymorphic forms of an antidiabetic agent, the process for their preparation, and pharmaceutical compositions thereof
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063209A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
EP1171431A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
JP2002542218A (en) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ New compounds, their manufacture and use
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
EP2100901A1 (en) 1999-05-17 2009-09-16 ConjuChem Biotechnologies Inc. Modified Insulin and conjugates thereof
DK1180121T3 (en) 1999-05-17 2004-03-01 Conjuchem Inc Long-acting insulinotropic peptides
BR0111562A (en) * 2000-06-16 2003-04-15 Lilly Co Eli Glucagon-like peptide 1 analogs
AU8760001A (en) 2000-07-20 2002-02-05 Hoffmann La Roche Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
WO2003062290A1 (en) 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
AU2003303634B2 (en) 2002-12-27 2009-10-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1503283A1 (en) 2003-08-01 2005-02-02 Hewlett-Packard Development Company, L.P. Data processing system and method
EP1660531A2 (en) * 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
RU2401276C2 (en) 2003-09-19 2010-10-10 Ново Нордиск А/С Glucagon-like peptide-1 (glp-1) derivatives
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN101380476A (en) 2003-09-19 2009-03-11 诺沃挪第克公司 Albumin-binding derivatives of therapeutic peptides
EP3153181A1 (en) 2004-11-12 2017-04-12 Bayer HealthCare LLC Site-directed modification of fviii bdd
CN101160326B (en) 2005-02-23 2013-04-10 利普生技术有限公司 Activated sialic acid derivatives for protein derivatisation and conjugation
JP2008533104A (en) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ GLP-1 receptor dimer peptide agonist
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006103298A2 (en) 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
KR101349808B1 (en) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 Novel compounds and their effects on feeding behaviour
WO2006134148A2 (en) 2005-06-15 2006-12-21 Novo Nordisk Health Care Ag Transglutaminase mediated conjugation of growth hormone
WO2007009894A2 (en) 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007087711A1 (en) 2006-01-31 2007-08-09 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
CN101389648B (en) 2006-02-22 2013-07-17 默沙东公司 Oxyntomodulin derivatives
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (en) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 Pegylated factor viii
JP2009544327A (en) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Glycosylation of peptides with O-linked glycosylation sequences
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN103804489A (en) 2006-12-15 2014-05-21 巴克斯特国际公司 Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2162535A4 (en) 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using n-acetylglucosaminyl transferases
JP5356373B2 (en) 2007-06-15 2013-12-04 ナショナル リサーチ カウンシル オブ カナダ Engineered version of polysialyltransferase with improved enzyme properties
ATE520714T1 (en) 2007-06-15 2011-09-15 Zealand Pharma As GLUCAGON ANALOGUE
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
ES2532116T3 (en) * 2007-09-05 2015-03-24 Novo Nordisk A/S Peptides derived with A-B-C-D and their therapeutic uses
WO2009039984A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Therapeutic uses of urocortin ii and kisspeptin ( 27-54 )
GB2467700A (en) 2007-11-09 2010-08-11 Baxter Int Modified recombinant Factor VIII and von Willebrand Factor and methods of use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CN101965200B (en) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 Conjugated factor VIII molecules
EA019203B9 (en) * 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon/glp-1 receptor co-agonists
US9062124B2 (en) 2008-06-17 2015-06-23 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
KR20110039230A (en) * 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
AU2009280017B2 (en) 2008-08-07 2013-01-10 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
PL2349342T3 (en) 2008-10-17 2019-01-31 Baxalta GmbH Modified blood factors comprising a low degree of water soluble polymer
EA020537B1 (en) * 2008-12-15 2014-11-28 Зилэнд Фарма А/С Glucagon analogues
US8680049B2 (en) 2008-12-15 2014-03-25 Zealand Pharma A/S Glucagon analogues
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
EP2370461B1 (en) 2008-12-15 2013-10-02 Zealand Pharma A/S Glucagon analogues
CN102333788A (en) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 Modification of factor viii
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
US20130053310A1 (en) 2010-03-26 2013-02-28 Novo Nordisk A/S Novel glucagon analogues
AR080592A1 (en) 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
EP2552950A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
AR081975A1 (en) 2010-06-23 2012-10-31 Zealand Pharma As GLUCAGON ANALOGS
EA201291234A1 (en) * 2010-06-24 2013-07-30 Зилэнд Фарма А/С ANALOGUE GLUACAGONA
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
PE20140186A1 (en) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS PRESENTING GIP RECEPTOR ACTIVITY
AR084558A1 (en) 2010-12-22 2013-05-22 Marcadia Biotech METHODS TO TREAT METABOLIC DISORDERS AND OBESITY WITH ACTIVE GLUCAGON-BASED PEPTIDES FOR THE GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) / PEPTIDO-1 SIMILAR TO GLUCAGON (GLP-1)
BR112013018269A2 (en) 2011-01-20 2017-06-06 Zealand Pharma As combination of acylated glucagon analogs with insulin analogs
JP2014510739A (en) 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス New glucagon analogues
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CA2836573C (en) 2011-05-18 2022-06-07 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
US10471127B2 (en) 2011-05-18 2019-11-12 Mederis Diabetes, Llc Peptide pharmaceuticals for insulin resistance
SG195258A1 (en) 2011-06-10 2013-12-30 Hanmi Science Co Ltd Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
MX2013015168A (en) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists.
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
EP2758426B1 (en) 2011-09-23 2019-08-07 Novo Nordisk A/S Novel glucagon analogues
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use

Also Published As

Publication number Publication date
US20130079278A1 (en) 2013-03-28
ZA201401603B (en) 2015-02-25
JP2014527975A (en) 2014-10-23
TWI596110B (en) 2017-08-21
US20130288958A1 (en) 2013-10-31
AU2012311484A1 (en) 2014-03-06
US9486505B2 (en) 2016-11-08
JP6352806B2 (en) 2018-07-04
US9486506B2 (en) 2016-11-08
BR112014006684A2 (en) 2017-03-28
MY167234A (en) 2018-08-14
JP2018021081A (en) 2018-02-08
TW201329102A (en) 2013-07-16
EP2758426B1 (en) 2019-08-07
IL231199A0 (en) 2014-04-30
US8541368B2 (en) 2013-09-24
CN104093735A (en) 2014-10-08
CA2849673A1 (en) 2013-03-28
RU2017101333A (en) 2018-12-19
MX354705B (en) 2018-03-16
RU2610175C2 (en) 2017-02-08
RU2014114434A (en) 2015-10-27
EP2758426A1 (en) 2014-07-30
AR088161A1 (en) 2014-05-14
MX2014003312A (en) 2014-04-25
AU2012311484B2 (en) 2017-04-13
CN104093735B (en) 2018-07-06
US20160347812A1 (en) 2016-12-01
WO2013041678A1 (en) 2013-03-28
KR20140070612A (en) 2014-06-10
US20150182594A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
IN2014CN02448A (en)
MX2013011175A (en) Novel glucagon analogues.
MX336412B (en) Novel glucagon analogues.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2014015423A (en) Exendin-4 peptide analogues.
MX2015008114A (en) Exendin-4 Derivatives.
IL239488B (en) Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
EA201201657A1 (en) TREATMENT OF DIABETES
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
IN2014KN02335A (en)
AU2013298343A8 (en) Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof
PL2852400T3 (en) An insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
GB201304462D0 (en) Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance
UA53217U (en) Mask for therapy and general health improvement
UA53455U (en) PПaЎ±б
UA78287U (en) Method for medical rehabilitation of patients with ischemic heart disease in setting of metabolic syndrome
MD4537B1 (en) Injectable supersaturated acetaminophen solution for spinal administration